 - Participants with a known anaplastic lymphoma kinase ALK fusion oncogene must be documented in the participants chart must have also experienced disease progression or intolerance with a first-line ALK Tyrosine Kinase Inhibitor TKI approved for the treatment of ALK fusion oncogene NSCLC for example, crizotinib. Disease progression or intolerance must be documented 